Propionates

Calcium Propionate Market Report 2021 - Global Industry Size, Competition, Trends and Growth Opportunities to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021
Chemicals, Plastics, Manufacturing, Chemistry, Chemical elements, Physical sciences, Calcium compounds, Calcium, Calcium propanoate, Propionates, Propionic acid, Calcium in biology

This study endeavors to evaluate different scenarios of COVID-19's impact on the future of the Calcium Propionate market from 2001 to 2028.

Key Points: 
  • This study endeavors to evaluate different scenarios of COVID-19's impact on the future of the Calcium Propionate market from 2001 to 2028.
  • Calcium Propionate Market Analysis by Types, Applications and Regions
    The research estimates global Calcium Propionate market revenues in 2021, considering the Calcium Propionate market prices, supply, demand, and trade analysis across regions.
  • The report covers North America, Europe, Asia-Pacific, Middle East, Africa, and LATAM Calcium Propionate market statistics from 2020 to 2028 with further division by leading product types, processes, and distribution channels of Calcium Propionate.
  • The status of the Calcium Propionate market in 16 key countries across the world is elaborated to enable an in-depth understanding of the Calcium Propionate industry.

Global Low-calorie Food Market Trajectory & Analytics Report 2020-2027: Aspartame is Projected to Account for US$2.6 Billion of the $10.1 Billion Total Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 20, 2021
Food, Beverage, Retail, Organic compounds, Sugar substitutes, Aspartame, Dipeptides, Propionates, Chemistry, Carbonyl compounds

The "Low-calorie Food - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Low-calorie Food - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Aspartame, one of the segments analyzed in the report, is projected to grow at a 4.3% CAGR to reach US$2.6 Billion by the end of the analysis period.
  • This segment currently accounts for a 30.2% share of the global Low-calorie Food market.
  • In the global Stevia segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment.

Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

Retrieved on: 
Monday, December 28, 2020
Carbonyl compounds, Organic compounds, Oxygen compounds, Bristol-Myers Squibb, Paclitaxel, Propionates, Taxanes

"We are very pleased to announce our partnership with Inceptua to make Apealea (paclitaxel micellar) available to patients with ovarian cancer in Europe," said Alex Kim, Chief Executive Officer of Elevar Therapeutics.

Key Points: 
  • "We are very pleased to announce our partnership with Inceptua to make Apealea (paclitaxel micellar) available to patients with ovarian cancer in Europe," said Alex Kim, Chief Executive Officer of Elevar Therapeutics.
  • This agreement further propels progress for Apealea development and commercialization, an important step in Elevar's strategy to optimize the value of its portfolio in global markets."
  • Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe.
  • "We are delighted to enter into this agreement with Elevar to commercialize Apealea (paclitaxel micellar) in Europe," said Stefan Fraenkel, Chief Executive Officer of Inceptua.

Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

Retrieved on: 
Monday, December 28, 2020
Carbonyl compounds, Organic compounds, Oxygen compounds, Bristol-Myers Squibb, Paclitaxel, Propionates, Taxanes

"We are very pleased to announce our partnership with Inceptua to make Apealea (paclitaxel micellar) available to patients with ovarian cancer in Europe," said Alex Kim, Chief Executive Officer of Elevar Therapeutics.

Key Points: 
  • "We are very pleased to announce our partnership with Inceptua to make Apealea (paclitaxel micellar) available to patients with ovarian cancer in Europe," said Alex Kim, Chief Executive Officer of Elevar Therapeutics.
  • This agreement further propels progress for Apealea development and commercialization, an important step in Elevar's strategy to optimize the value of its portfolio in global markets."
  • Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe.
  • "We are delighted to enter into this agreement with Elevar to commercialize Apealea (paclitaxel micellar) in Europe," said Stefan Fraenkel, Chief Executive Officer of Inceptua.

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Retrieved on: 
Friday, December 11, 2020
Nonsteroidal anti-inflammatory drugs, Naproxcinod, Propionates, NicOx, COX-inhibiting nitric oxide donator, Fera

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced today that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced today that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.
  • Nicox and Fera entered into an agreement in December 2015 which granted Fera exclusive rights to develop and commercialize naproxcinod for the U.S. market.
  • Nicox and Fera are amending their existing agreement to include COVID-19 as an indication, and Nicox will grant to Fera warrants1 to acquire 10,000 Nicox shares.
  • Once Fera has received the newly manufactured naproxcinod, they plan to initiate proof-of-concept pre-clinical tests in models of COVID-19 infection.

Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)

Retrieved on: 
Tuesday, December 1, 2020
Carbonyl compounds, Organic compounds, Oxygen compounds, Bristol-Myers Squibb, Paclitaxel, Propionates, Taxanes

Apealea received market authorization by the European Commission in November 2018, making it Europe's first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer.

Key Points: 
  • Apealea received market authorization by the European Commission in November 2018, making it Europe's first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer.
  • Elevar Therapeutics has offices in Utah, California and South Korea, and additional information is available at www.elevartherapeutics.com .
  • Tanner Pharma Group is a specialist pharmaceutical services provider based in Charlotte, USA with offices in Europe and Latin America.
  • Over 18 years, Tanner has developed a portfolio of service offerings focused on improving the global access to medicines.

6-Month Data From the Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020

Retrieved on: 
Monday, November 9, 2020
General Health, Surgery, Medical devices, Health, Cardiology, Carbonyl compounds, Organic compounds, Oxygen compounds, Bristol-Myers Squibb, Paclitaxel, Propionates, Taxanes, DCB, the Avess DCB, Surmodics, Inc.

The Avess DCB is a next-generation DCB that may provide further clinical benefits while minimizing systemic paclitaxel exposure.

Key Points: 
  • The Avess DCB is a next-generation DCB that may provide further clinical benefits while minimizing systemic paclitaxel exposure.
  • Data presented include 6-month results from 12 patients treated with an Avess DCB between December 2018 and August 2019.
  • We are quite pleased with the AVESS first-in-human study results, which provide vital safety data on the Avess DCB and directional data on its effectiveness.
  • The design of the Avess DCB reflects Surmodics long-standing industry leadership in the development of surface technology for vascular medical devices.

Mivacurium Chloride (CAS 106861-44-3) Market Research Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 31, 2019
Manufacturing, Chemicals, Plastics, Chemical compounds, Chemistry, Physical sciences, Chlorides, Nicotinic antagonists, Tetrahydroisoquinolines, Mivacurium chloride, Propionates, Market research

The "Mivacurium chloride (CAS 106861-44-3) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mivacurium chloride (CAS 106861-44-3) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on researching the world market of Mivacurium chloride.
  • The report helps to build up a clear view of the market (trends and prospects), identify major players in the industry, and estimate main downstream sectors.
  • The Mivacurium chloride global market Report 2019 key points:

Global Mivacurium Chloride (CAS 106861-44-3) Markets 2019 - Applications, Manufacturing Methods, Patents, Suppliers, Prices & End-Users

Retrieved on: 
Friday, May 31, 2019
Chemical compounds, Chemistry, Physical sciences, Chlorides, Nicotinic antagonists, Tetrahydroisoquinolines, Mivacurium chloride, Propionates, Market research

DUBLIN, May 31, 2019 /PRNewswire/ -- The "Mivacurium chloride (CAS 106861-44-3) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 31, 2019 /PRNewswire/ -- The "Mivacurium chloride (CAS 106861-44-3) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on Researching the world market of Mivacurium chloride.
  • The report helps to build up a clear view of the market (trends and prospects), identify major players in the industry, and estimate main downstream sectors.
  • The Mivacurium chloride global market Report 2019 key points:

Hyoscine-N-Butyl Bromide Market Forecast, Trend Analysis & Competition Tracking- Global Market Insights 2018-2027

Retrieved on: 
Monday, May 27, 2019
Chemistry, Physical sciences, Natural sciences, Muscarinic antagonists, Propionates, RTT, Butyl bromide, Bromoalkanes, Hyoscine, Butyl group, Bromine, 1-Bromobutane

NEW YORK, May 27, 2019 /PRNewswire/ --The latest report on the Hyoscine-N-Butyl Bromide market published provides in-depth analysis along with the valuable and actionable insights on the market.

Key Points: 
  • NEW YORK, May 27, 2019 /PRNewswire/ --The latest report on the Hyoscine-N-Butyl Bromide market published provides in-depth analysis along with the valuable and actionable insights on the market.
  • It also offers details on all the important factors influencing the Hyoscine-N-Butyl Bromide market growth.